A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission

@article{Levine2007API,
  title={A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission},
  author={Douglas A. Levine and Kay J. Park and Margrit M. Juretzka and Julie Esch and Martee L. Hensley and Carol Aghajanian and Sharyn N. Lewin and Jason A Konner and Felicia Derosa and David R Spriggs and Alexia Iasonos and Paul Sabbatini},
  journal={Cancer},
  year={2007},
  volume={110}
}
The current study was conducted to determine the effect of goserelin and bicalutamide on progression‐free survival (PFS) in patients with epithelial ovarian cancer who were in second or greater complete disease remission. 
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.
TLDR
Abagovomab administered as repeated monthly injections is safe and induces a measurable immune response and Administration as maintenance therapy for patients with ovarian cancer in first remission does not prolong RFS or OS. Expand
Consolidation strategies in ovarian cancer: observations for future clinical trials.
TLDR
Preliminary benchmarks for efficacy endpoints are suggested for future consolidation trials of patients in cCR, however, the suggested strategies will require validation in randomized trials and larger data sets. Expand
Issues in the Design of Ovarian Cancer Trials Evaluating Antineoplastic Agents Not Predicted to Cause Regression of Existing Tumor Masses
Abstract Despite the conduct of numerous randomized clinical trials in advanced ovarian cancer over the past decade, no new primary chemotherapeutic regimen has demonstrated a major improvement inExpand
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037)
TLDR
The Cancer of the Ovary Abiraterone (CORAL) trial represents the first trial of an AR targeted agent in ovarian cancer and a subset of patients achieved sustained clinical benefit. Expand
Identifying Clinical Improvement in Consolidation Single-Arm Phase 2 Trials in Patients With Ovarian Cancer in Second or Greater Clinical Remission
TLDR
Designs of nonrandomized consolidation trials that aim to prolong PFS must consider the effect of the duration of SLT on the end point definition and on required sample size. Expand
Consolidation Therapy in Ovarian Cancer: A Clinical Update
  • P. Sabbatini
  • Medicine
  • International Journal of Gynecologic Cancer
  • 2009
TLDR
As treatment options move beyond classic chemotherapy to novel hormones, immune interventions, and biologic agents, the consolidation strategy is regaining interest and is particularly attractive in that many of these agents have stable disease as best outcome, and this is most appropriate to evaluate in patients with minimal volume disease. Expand
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
TLDR
The CBR of 19% observed with bicalutamide shows proof of principle for the efficacy of minimally toxic androgen blockade in a select group of patients with ER/PgR-negative, AR-positive breast cancer. Expand
Significance of ERCC1 and Hormonal Receptor Expression in Ovarian Cancer.
TLDR
It is demonstrated that positive ERCC1 expression is not associated with clinical resistance to platinum-based chemotherapy, ER CC1, AR& ER expression are not independent factors affecting the prognosis of patients with epithelial ovarian tumors and not related with survival benefits. Expand
Hormone response in ovarian cancer: time to reconsider as a clinical target?
TLDR
It is proposed that it is timely to perform additional well-designed trials that should include biomarkers of response and increasing evidence from in vitro studies that estrogen, progestin, and androgen regulate proliferation and invasion of epithelial ovarian cancer cells. Expand
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
TLDR
There may be little or no difference between treatment with leuprorelin or treosulfan in overall survival (OS) or progression-free survival (PFS) at six and 12 months, and neurotoxicity (RR 0.65, 95% CI 0.12 to 3.66) and neutropenia (very low-quality evidence). Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial
5000 Background: Bev is a recombinant humanized anti-VEGF monoclonal antibody that inhibits the growth of a number of human cancers, including ovarian cancer. Low dose chronic chemotherapy (metrono...
Leuprolide acetate as a salvage-therapy in relapsed epithelial ovarian cancer.
TLDR
The data stress the significant activity of Leuprolide acetate as a salvage therapy in patients with relapsed advanced epithelial ovarian cancer after previous platinum-based chemotherapies. Expand
A Phase II Trial of Leuprolide Acetate in Patients with Advanced Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study
TLDR
Leuprolide acetate was well tolerated but has insignificant activity in treating patients with chemotherapy-refractory ovarian adenocarcinoma. Expand
Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients
TLDR
A signature of predictive markers, including low HER2 expression, predicts response in the first study of a hormonal agent in a preselected group of ER-positive ovarian cancer patients. Expand
Consolidation for ovarian cancer in remission.
  • P. Sabbatini, D. Spriggs
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
The SMART study, evaluating intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody (Y-muHMFG1), described in this issue of the Journal of Clinical Oncology, was logically based and appropriately designed and adequately powered, with the outcome reminding all that randomized trials are the only reasonable way to move cancer therapy forward. Expand
Second‐line therapy of advanced ovarian cancer with GnRH analogs
TLDR
The high tolerability and the results obtained with leuprolide versus platinum in second-line therapy might permit a better use of the analogs for advanced ovarian cancer. Expand
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
TLDR
The length of a prior response to platinum-based therapy in ovarian cancer is highly predictive of the upper limit of the duration of response to a subsequent platinum program, assuming the same or similar drugs are used. Expand
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.
TLDR
The median PFS from second complete remission is short and a second response is rarely longer than the first even in this second CR population, exploring benchmarks for future consolidation strategies. Expand
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
  • R. Ozols, B. Bundy, +7 authors R. Baergen
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin pluspaclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus pac Litaxel. Expand
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
TLDR
Paclitaxel plus platinum chemotherapy seems to improve survival and progression-free survival among patients with relapsed platinum-sensitive ovarian cancer compared with conventional platinum-based chemotherapy. Expand
...
1
2
3
4
...